Syra Health Achieves 23% Revenue Growth, Improves Gross Margin to 44.5% in Second Consecutive Profitable Quarter
Syra Health Corp (SYRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Syra Health Achieves 23% Revenue Growth, Improves Gross Margin to 44.5% in Second Consecutive Profitable Quarter ● Syra Health sustained profitability in Q2 2026, following the Company’s first profitable quarter in Q1 2026, delivering net income of $250,242 compared
How this was made
The 30-second read
Why it matters
The filing is a direct earnings and operational update: it quantifies a return to profitability, margin expansion, and provides new contract-related catalysts plus a stated focus on full-year profitability for 2026.
Market read
Traders can update near-term expectations for SYRA based on quantified profitability and margin improvement, plus incremental contract wins and a potential CMS program catalyst.
What to watch
Cash fell from $2.9M to $2.1M despite operating cash inflow, and deferred revenue recognition plus accounts receivable growth may warrant scrutiny for future quarter quality.
Background
This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 summarizing Syra Health’s Q2 2026 results and operational updates, including contract extensions and an expected CMS ACCESS Model approval.
Ticker impact
Syra Health reported Q2 2026 net income of $250,242, revenue up 23% to $2.4M, and gross margin rising to 44.5%.
Near-term upside bias as traders re-rate the likelihood of sustained 2026 profitability, but OTC liquidity may limit follow-through.
The filing provides fresh quarterly financial datapoints (net income, EPS, gross margin, EBITDA) and new operational items (renewals and CMS ACCESS Model approval expectation) that can change forward expectations.
Market effects
Supports the narrative that prevention-focused healthcare services can scale profitably, potentially improving sentiment toward small-cap healthcare services.
Limited, as contract renewals are state-level (North Carolina, Indiana) and not broad macro demand signals.
Low, company-specific results with no stated international expansion or global regulatory change.
Counterpoint
Profitability may be partly timing-driven (revenue recognition, contract milestones), so margin durability could be less certain than the headline suggests.
Key entities
- issuerSyra Health Corp.
OTCQB-listed healthcare solutions company reporting Q2 2026 profitability, revenue growth, and gross margin expansion.
- customerWake County Public Health
Received a one-year renewal of Syra Health’s public health contract in North Carolina.
- customerIndiana Veterans’ Home
Received a one-year extension of Syra Health’s healthcare workforce contract.
- government agencyIndiana FSSA (Division of Disability and Rehabilitative Services)
Syra Health received an amendment to extend a learning management platform through October 2028.
- program/partnerCMS ACCESS Model (with HealthSync)
Syra Health anticipates approval in the near term, expected to be a durable revenue source over the next 10 years.
